LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance

• Published in: Biochemical pharmacology Vol. 189; p. 114228
• Main Authors: Zhou, Ying, Sun, Wen, Qin, Zhiyuan, Guo, Suhang, Kang, Yu, Zeng, Su, Yu, Lushan
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.07.2021
• Subjects: Bioinformatics tools; Chemoresistance; Epigenetics; LncRNA; LncRNA; Epigenetics; Bioinformatics tools; Chemoresistance
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2020.114228

[Display omitted] Long-noncoding RNAs (lncRNAs) have been shown to participate in sensitizing or de-sensitizing cancer cells to chemical drugs during cancer therapeutics. Notably, a plethora of lncRNAs have been confirmed to be associated with epigenetic controllers and regulate histone protein modification or DNA methylation states in the process of gene transcription. This correlation between lncRNAs and epigenetic regulators can induce the expression of core genes to trigger drug resistance. In addition, epigenetic signatures are considered to be effective and attractive biomarkers for monitoring drug therapeutic effects because they are inheritable, dynamic, and reversible. Therefore, the regulatory mechanism between lncRNAs and epigenetic machinery can serve as a novel indicator and target to overcome or reverse drug resistance in cancer therapy. In this review, we also presented a curated selection of computational tools (including online databases and network analysis) in the area of epigenetics. A classic workflow for lncRNA expression network analysis is presented, providing guidance for non-bioinformaticians to identify significant correlation between lncRNAs and other biomolecules.